Efficacy and safety of sofosbuvir/velpatasvir in a real‐world chronic hepatitis C genotype 3 cohort-Reference-Cited by-同舟云学术

Efficacy and safety of sofosbuvir/velpatasvir in a real‐world chronic hepatitis C genotype 3 cohort

Published:2020-12-05 Issue:5 Volume:36 Page:1300-1308
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Wong Yu Jun¹²^ORCID,Thurairajah Prem Harichander¹²³,Kumar Rahul¹,Tan Jessica¹,Fock Kwong Ming¹²,Law Ngai Moh¹²,Li Weiquan¹,Kwek Andrew¹,Tan Yu Bin¹,Koh Jingyun¹,Lee Zheng Cong¹,Kumar Loshini Senthil¹,Teo Eng Kiong¹²,Ang Tiing‐Leong¹²^ORCID

Affiliation:

1. Department of Gastroenterology and Hepatology Changi General Hospital Singapore

2. Yong Loo Lin School of Medicine National University of Singapore Singapore

3. Division of Gastroenterology and Hepatology National University of Singapore Singapore

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15324

Reference24 articles.

1. WHO.Global hepatitis report 2017. Geneva: World Health Organization.2017.http://www.who.int/hepatitis/publications/global‐hepatitis‐report2017/en(accessed Sept 2018)

2. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes

3. The Risk of Long-term Morbidity and Mortality in Patients With Chronic Hepatitis C

4. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

5. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis;eClinicalMedicine;2024-08

2. Pharmacologic Treatment of Portal Hypertension;Clinics in Liver Disease;2024-08

3. Direct-Acting Antiviral Therapy for Patients with Chronic Hepatitis C Infection and Decompensated Cirrhosis;Digestive Diseases and Sciences;2024-04-05

4. Treatment with Sofosbuvir/Velpatasvir of the most difficult to cure HCV-infected population;Polish Archives of Internal Medicine;2024-01-02

5. An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats;Environmental Science and Pollution Research;2023-08-09